Risperdal Lawyers at Bernstein Liebhard LLP Comment on Growing Litigation, As Cases in Philadelphia Mass Tort Mount

Share Article

The Firm is actively filing Risperdal gynecomastia claims in the Philadelphia proceeding, all of which allege that the medication caused men and boys to experience excessive breast growth.

Free Case Review
Our Firm is actively filing Risperdal lawsuits in the Philadelphia proceeding on behalf of men and young boys who allegedly sustained gynecomastia and other complications resulting from use of the medication.

Bernstein Liebhard LLP notes the filing of more than 1,200 Risperdal lawsuits (http://www.risperdallawsuit2014.com/) in a Pennsylvania state litigation established for cases over the antipsychotic medication.

According to court records, more than 1,203 claims are now pending in the Philadelphia Court of Common Pleas. These cases were filed on behalf of individuals who allegedly developed gynecomastia and other complications due to their use of Risperdal, which is manufactured by Johnson & Johnson and Janssen Pharmaceuticals. Plaintiffs in these cases accuse these companies of failing to properly warn about side effects that may stem from use of its product. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm is actively filing Risperdal lawsuits in the Philadelphia proceeding on behalf of men and young boys who allegedly sustained gynecomastia and other complications resulting from use of the medication. It is not surprising that the the number of claims involving this and other alleged Risperdal side effects has surpassed 1,200 cases,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm continues to evaluate potential Risperdal lawsuits on behalf of men and young boys who allegedly experienced excessive breast growth because of the medication.

Risperdal Gynecomastia Allegations
Risperdal is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar disorder in adults and adolescents ages 10-to-17, as well as symptoms associated with irritability in children between 5-and-16 years old with autism. According to recent research, the medication is often prescribed off-label for children with ADHD, even though it has not been specifically approved for such purposes by the FDA.*

All the 1,200 Risperdal lawsuits now pending in the Philadelphia Court of Common Pleas accuse Johnson & Johnson and Janssen of failing to adequately warn about gynecomastia and other complications allegedly associated with its product, and even concealing certain information that may have placed thousands of individuals at risk. Specifically, those represented by Bernstein Liebhard LLP allege that the companies withheld Risperdal’s potential to cause elevated levels of prolactin, a hormone typically associated with breast development in young girls and lactation in new mothers. This may result in breast swelling, tenderness, nipple discharge and other painful and embarrassing side effects, lawsuits further allege.

Johnson & Johnson and Janssen have also improperly marketed Risperdal for uses not approved by the FDA, according to a number of product liability claims and charges from the U.S. federal government, whose claims against the companies resulted in a historic settlement reached in November 2013. According to the U.S. Department of Justice, Risperdal’s manufacturers agreed to pay $2.2 billion to resolve charges involving their marketing of this and other medications at this time, which has become one of the largest healthcare fraud settlements in history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and young boys who allegedly developed gynecomastia after taking Risperdal may be eligible to receive compensation for out-of-pocket medical bills, lost wages, pain and suffering and other damages. Learn more about Risperdal gynecomastia complications when you visit Bernstein Liebhard LLP’s website. Call the following toll-free number for a free and confidential case evaluation: 800-511-5092.

*health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website